Inflection: Pairing up PIM

Inflection combines pan-PIM kinase, PI3K, mTOR inhibitors in single molecule

Inflection Biosciences Ltd. is developing pan-PIM kinase inhibitors that are a few years behind large pharma competitors, but the biotech's compounds can be structurally linked to other kinase inhibitors for cancer. The small molecules thus could address multiple pathways with a single compound, simplifying combination therapy.

PIM kinases are a family of serine threonine kinases involved in cell cycle regulation, apoptosis,

Read the full 601 word article

How to gain access

Continue reading with a
two-week free trial.